Systemic Sclerosis

An Update

Uwe-Frithjof Haustein, MD, PhD

Disclosures

Lab Med. 2011;42(9):562-572. 

In This Article

Antifibrotic Agents

Imatinib mesylate, an inhibitor of the tyrosine kinase, also targets the PDGFR kinase, thus inhibiting the ERK1/2 pathway of FB activation. Various clinical studies have shown it reduces fibrosis of different organs.[101]

Oral administration of 500 mg bovine collagen type I reduced skin thickness. The rationale is the induction of oral tolerance against the suspected autoantigen collagen as measured by T cell reactivity.[103] However, the target of this therapy may only be a secondary mechanism.

Attempts to treat with neutralizing anti-TGFβ antibodies (CAT-192) and with peptide inhibitors of TGFβ and CTGF are promising. Penicillamine cannot be recommended, since it causes severe side effects.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....